To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes.
with type 1 diabetes (4). However, the evidence base for such treatments is limited (5) , and only pramlintide, an analog of human amylin (6) , is currently approved by the U.S. Food and Drug Administration for use with mealtime insulin in people with type 1 diabetes (7) .
In people with type 2 diabetes, liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is known to stimulate insulin secretion, improve b-cell function, and inhibit glucagon release from a-cells in a glucose-dependent manner (8) . Furthermore, liraglutide decreases food intake (9) and has weight loss benefits in type 2 diabetes (10) (11) (12) (13) (14) . Whether similar responses exist in people with type 1 diabetes is uncertain. Small, nonrandomized studies in subjects with type 1 diabetes suggest that GLP-1RA treatment results in reduction in fasting and postprandial hyperglycemia, postprandial glucagon plasma levels, glucose excursions, hypoglycemic events, insulin requirements, and body weight, but these results have not yet been confirmed in larger studies with longer duration (15) (16) (17) (18) (19) (20) (21) (22) (23) . Recently, two such randomized controlled trials (RCTs) investigating the efficacy and safety of liraglutide added to insulin in subjects with type 1 diabetes have been completed (ADJUNCT ONE [NCT01836523] [24] and ADJUNCT TWO [NCT02098395]). Here we report findings from the ADJUNCT TWO trial.
The primary aim of ADJUNCT TWO was to confirm, in a large, multicenter, randomized study, superiority of liraglutide compared with placebo, both adjunct to capped insulin treatment, on glycemic control, after 26 weeks of treatment in subjects with established type 1 diabetes and inadequate glycemic control.
RESEARCH DESIGN AND METHODS

Trial Design
This was a 26-week, randomized, insulincapped, placebo-controlled, double-blind, parallel-group, phase 3 trial performed at 59 centers in North America, Europe, and Africa.
After a screening visit (week -2), eligible subjects attended the randomization visit (week 0) and were randomized using a telephone or web-based system (IV/WRS) by Novo Nordisk (Clinical Supplies Coordination) ( ). Subjects were randomized 3:1 to liraglutide 1.8, 1.2, and 0.6 mg, or liraglutide placebo 0.3, 0.2, or 0.1 mL, respectively, as adjunct to insulin treatment for a period of 26 weeks. Treatment with liraglutide (or the corresponding placebo volume) was started at 0.6 mg/day at week 0 and increased by 0.6 mg every 2nd week until the randomized dose level was reached. In order to obtain a dose response, dose reduction of liraglutide was not permitted on randomized dose.
To ensure treatment uniformity between the trial sites, as well as to ensure that subjects received treatment according to the trial protocol, titration algorithms were developed specifying recommended insulin dose adjustments at different plasma glucose levels. Subjects were instructed to perform selfmonitoring of plasma glucose (SMPG) (4-, 7-, and 9-point profiles) on days before site and phone contacts and after new liraglutide dose escalation. The insulin cap was determined for each subject individually prior to randomization and, as it is acknowledged that people with type 1 diabetes can have large fluctuations in insulin dose on a daily basis, was defined as the average of the previous 7 consecutive days' total daily insulin dose. No range limit or lower limit for insulin requirement was set. No postprandial glucose targets were set. However, adjustments based on postprandial glucose within the limits of the insulin cap were at the discretion of the investigator in accordance with local practice/standard of medical care. The total daily prerandomization insulin dose was reduced by 25% for at least 1 day when liraglutide or placebo was initiated, and by a further 10% for at least 1 day when liraglutide/placebo doses were escalated. Thereafter, the insulin dose could be adjusted weekly by subjects and at least biweekly by investigators, based on 4-point glucose (premeal) values, toward the insulin cap as defined previously. In case of severe deterioration of glycemic control, rescue treatment was to be initiated ( Supplementary Fig. 1 ). 
Statistical Analyses
Sample size was determined to detect a difference of 0.4% (4.4 mmol/mol) in HbA 1c change and 2.5 kg in body weight change after 26 weeks of treatment between the liraglutide 1.8 mg dose and placebo with 90.0 and 99.9% power, respectively. Sample size calculation was based on a two-sided Student t test of 5% and an SD of 1.1% (12.0 mmol/mol) in HbA 1c change after 26 weeks of treatment. The required sample size was 160 subjects per group, assuming no patients withdrew. Adopting an overall 20% dropout rate evenly distributed among treatment groups, the required sample size was 200 subjects per group. With a 50% efficacy retention in the dropouts, a treatment difference of 0.36% was then expected.
Continuous data were analyzed using a mixed model for repeated measurements, with treatment, stratification, and country as fixed factors and baseline as a covariate, all nested within visit. Binary data were analyzed by a logistic regression model, with treatment and stratification as factors and HbA 1c value at baseline as a covariate. Missing HbA 1c data were imputed from the mixed model for repeated measurements used for the analysis of HbA 1c . Numbers of on-treatment hypoglycemic/ hyperglycemic episodes were analyzed using a negative binomial regression model, with a log-link function and the logarithm of the time period in which the episodes were considered treatment emergent as offset, with treatment, stratification, and country as factors and the HbA 1c value at baseline as a covariate.
RESULTS
Subject Disposition
Of the 835 randomized subjects, 832 were exposed to liraglutide or placebo in addition to insulin during the trial (liraglutide 0.6 mg, n = 211; 1.2 mg, n = 209; 1.8 mg, n = 206; placebo, n = 206) and 661 subjects completed week 26 without discontinuation of trial product or use of rescue treatment (intensification of usual insulin dose) (liraglutide 0.6 mg, n = 177; 1.2 mg, n = 157; 1.8 mg, n = 157; placebo, n = 170) (Supplementary Fig. 1 ). Overall, rescue treatment was needed in 42 (5.0%) subjects. More subjects in the liraglutide 1.2 mg group required rescue treatment (n = 16, 7.7%) than in the other treatment groups (liraglutide 1.8 mg: n = 8, 3.9%; 0.6 mg: n = 9, 4.2%; placebo: n = 9, 4.3%). In total, 127 (15.2%) subjects withdrew from the trial: n = 42 (20.3%), n = 32 (15.3%), n = 26 (12.3%), and n = 27 (13.0%) in the liraglutide 1.8, 1.2, and 0.6 mg and placebo groups, respectively.
Baseline Characteristics
On average, the trial population had longstanding (mean duration 21.1 years) type 1 diabetes with inadequate glycemic control (mean HbA 1c 8.1% [65.0 mmol/mol]) and was moderately overweight (mean body weight 83.9 kg; mean BMI 28.9 kg/m 2 ) ( Table 1 ). In total, 125 (15.2%) subjects had C-peptide levels greater than the lower limit of quantification (.LLOQ: 0.030 nmol/L) (Supplementary Table 1 ) and 213 (25.6%) subjects were receiving CSII. Overall, mean (geometric) total daily insulin dose was 10.0 units higher in subjects receiving MDI of insulin than in subjects receiving CSII. Almost half of the subjects had some symptoms or diagnosis of long-term diabetes complications, 47 (5.7%) subjects had hypoglycemia unawareness, and 61 (7.3%) had a history of severe hypoglycemia. (Fig. 1A) . The reduction in HbA 1c reported with liraglutide 1.8 mg was accompanied by a significantly greater increase in mean 1,5-anhydroglucitol compared with placebo (end-of-trial values: 3.11 mg/mL and 2.68 mg/mL, respectively; estimated treatment ratio: 1.16 [95% CI 1.05; 1.28], P = 0.0026) and, with the 9-point SMPG profiles, apparent reductions in postbreakfast, postlunch, and bedtime glucose ( Supplementary Fig. 2 ). With liraglutide 1.2 and 0.6 mg, there was no significant effect (compared with placebo) on 1,5-anhydroglucitol and no apparent reductions in 9-point SMPG profiles. There were no significant differences between any of the liraglutide doses and placebo for mean fasting plasma glucose, mean fasting plasma glucagon, or mean plasma C-peptide at 26 weeks.
A significant dose-dependent decrease in mean (geometric) total daily insulin dose was reported with all liraglutide doses at 26 weeks compared with placebo (estimated treatment ratio: 1. (Fig. 1B) . This insulin dose reduction in the liraglutide groups was achieved mainly through a prandial insulin reduction. The mean decrease of prandial insulin was -4 to -5 units and -3 to -5.5 units in subjects receiving MDI of insulin and CSII, respectively, whereas the dose decrease in basal insulin was -0.9 to 0.2 units and -0.1 to -0.9 units, respectively.
A dose-dependent statistically significant decrease in mean body weight from baseline to week 26 was reported with liraglutide (1.8 mg, -5.1 kg; 1.2 mg, -4.0 kg; 0.6 mg, -2.5 kg; placebo, -0.2 kg, all P , 0.0001) (Fig. 1C) (Fig. 2C) .
Safety
Overall, rates of AEs increased with liraglutide in a dose-dependent manner (11.5, 9.6, and 7.0 events per patient year of exposure [PYE] for liraglutide 1.8, 1.2, and 0.6 mg, respectively, compared with 6.3 events per PYE for placebo) (Table 2 ). However, there was a similar proportion of subjects with serious AEs across the treatment groups (6.8, 10.0, and 9.5% for liraglutide 1.8, 1.2, and 0.6 mg, respectively, compared with 6.8% for placebo). There was a higher rate of study discontinuation due to AEs in the liraglutide group than in the placebo group. Nausea, which increased dose dependently (2.0, 1.3, and 0.8 events per PYE for liraglutide 1.8, 1.2, and 0.6 mg, respectively, and 0.4 events per PYE for placebo), was the most frequently reported AE with liraglutide. In all liraglutide groups, new-onset nausea tended to occur within the first weeks of treatment (i.e., during dose initiation and escalation); after this time, the incidence of nausea decreased. Table 2 ). However, the majority of subjects in each treatment group had postbaseline lipase and amylase values within the normal range. There were transient elevations of lipase greater than three times the upper limit of normal in all liraglutide groups (1.8 mg, n = 4 [1.9%]; 1.2 mg, n = 4 [1.9%]; 0.6 mg, n = 2 [1.0%]). One subject in the placebo group had a transient elevation of amylase greater than three times the upper limit of normal. No cases of pancreatitis were reported in any treatment group. There was no apparent difference between the treatment groups in the proportion of subjects who had calcitonin categorized as either ,LLOQ or $LLOQ at weeks -2 and 26 as well as for median, minimum, and maximum values (Supplementary Table 2 ). Mean pulse and systolic blood pressure significantly increased and decreased, respectively, in all liraglutide treatment groups (Supplementary Table 2 ). There was no significant effect on mean diastolic blood pressure.
Hypoglycemic Episodes
In total, 92-98% of subjects reported at least one hypoglycemic episode during the trial, and hypoglycemic episodes were uniformly distributed throughout the trial period. For most hypoglycemia end points, the number of episodes was similar across treatment groups ( 
Subgroup Analyses
With the exception of C-peptide-positive/-negative subjects, the analyses of the previously mentioned subgroups showed comparable findings to the overall results. In the current trial, ;15% of subjects (n = 125) had C-peptide levels above the LLOQ, ranging between 0.08 and 0.12 nmol/L. These subjects also differed from the overall population by a slightly higher baseline HbA 1c and shorter type 1 diabetes duration (Supplementary Table 1 ). These subjects showed an improved treatment effect There was no significant effect of liraglutide 1.2 and 0.6 mg on TRIM-D total score compared with placebo. There was no overall effect of any dose of liraglutide on TRIM-HYPO total three domains score or short-form 36 overall physical or mental scores compared with placebo.
CONCLUSIONS
ADJUNCT TWO is the first large-scale RCT designed to investigate the efficacy and safety of adding liraglutide to an individually capped insulin dose in subjects with type 1 diabetes and inadequate glycemic control. The current trial demonstrates that liraglutide (1.8, 1.2, and 0.6 mg) added to capped insulin treatment results in greater mean reductions in HbA 1c , body weight, and insulin dose but higher rates of hypoglycemia (1.2 mg) and hyperglycemia with ketosis (1.8 mg) compared with placebo. These findings are largely in agreement with those from ADJUNCT ONE, a 52-week randomized, placebo-controlled, double-blind, parallel-group, treat-to-target, phase 3 trial carried out at 177 centers in 17 countries (24) . Considering efficacy, the mean reduction in HbA 1c reported with liraglutide 1.8 mg in the current trial was modest (despite the greatest decrease in pretrial insulin) but comparable to that achieved with pramlintide (-0.5% [-5.5 mmol/mol]) (27). Subgroup analysis in the current study indicates that in C-peptide-positive subjects, the mean placebo-corrected reduction in HbA 1c with liraglutide 1.8 mg is significantly greater than in C-peptide-negative subjects (i.e., -0.8 vs. -0.3%). In the overall analysis, with liraglutide 1.8 mg, there was an increase in mean 1,5-anhydroglucitol as well as nonsignificant (compared with placebo) reductions in postbreakfast, postlunch, and bedtime SMPG measurements that, together, suggest improvements in both overall and postprandial glycemic control. HbA 1c reductions that occurred were more pronounced within the first 3 months of the trial, after which HbA 1c levels steadily increased toward placebo levels. This suggests that insulin dose increases could have been more aggressive. Whether expected insulin-associated weight gain could have impacted the decision to intensify insulin treatment further throughout the trial remains speculative.
In the current trial, the insulin cap was imposed to reflect the added effect on glycemic control in people who, in clinical practice, may be reluctant to intensify insulin treatment. Despite the HbA 1c reduction obtained, the mean total daily insulin dose did not return to the mean cap, and mean total daily insulin doses were ;10-15% below baseline values at week 26. It is noteworthy that most, if not all, of the reduction in total daily insulin dose was due to prandial insulin. A recent study reports a reduction in carbohydrate intake, associated with appetite suppression, and a reduction in postprandial glucagon in subjects with type 1 diabetes being treated with liraglutide (28) . It could, therefore, be speculated that in the current study, liraglutide may have inhibited energy intake and postprandial glucagon secretion, thereby limiting the exogenous insulin requirement. However, in ADJUNCT TWO, neither possibility was specifically investigated.
Weight loss and improvements in quality of life were additional benefits of liraglutide treatment in the current trial. Liraglutide 1.8 mg resulted in a mean reduction in body weight of -5.1 kg, and this is comparable with findings from a recent RCT involving a population with type 1 diabetes and obesity (-6.8 kg) (22) . Intensive insulin treatment in people with type 1 diabetes is often associated with an increased prevalence of overweight and obesity over time (29) . In the DCCT study after 6 years of treatment, for example, 4.75 kg more weight gain than conventionally treated counterparts was observed (30). Furthermore, both overweight and obesity are associated with insulin resistance, dyslipidemia, increased blood pressure, and atherosclerosis in a population with type 1 diabetes (31). The improvement in quality of life as evidenced by the increased mean TRIM-D total score and the mean TRIM-D management score suggests that adjunctive liraglutide treatment may improve adherence with potential longer-term benefits (32-34). Considering safety, higher numbers of symptomatic hypoglycemia were seen with liraglutide (1.2 mg) than with placebo (21.3 vs. 16.6 events per PYE, respectively). An explanation as to why only one of the liraglutide doses showed higher rates remains unclear. It has been considered that this may relate to the insulin dose titration, nausea, satiety, or misjudged food intake. However, currently no specific reason is directly supported by collected data. Whether this is an intrinsic problem with the use of GLP-1RAs in type 1 diabetes or if it could be mitigated by patient selection, dosing, continuous glucose monitoring, or education remains speculative. It is of note that liraglutide added to insulin treatment does not affect the counter-regulatory hormone responses during hypoglycemia or glycemic recovery from hypoglycemia in subjects with type 1 diabetes (21,35) ; consequently, the higher incidence of hypoglycemia with liraglutide is probably not dependent on defective counter-regulation. Increased hyperglycemia with ketosis was also observed with liraglutide compared with placebo. In the liraglutide group, the reduction in daily total insulin dose may have contributed to this observation. Interestingly, whereas there were .80 events of hyperglycemia with ketosis in the C-peptide-negative population on liraglutide, there was only one event in the C-peptide-positive population. The increases in mean amylase, lipase, and pulse and reductions in mean systolic blood pressure reported in the liraglutide groups are of unknown clinical significance. Furthermore, these observations are similar to those seen in type 2 diabetesfocused trials involving this drug class (36) (37) (38) .
Considering trial limitations, the results may have benefited from the assessment of food intake; moreover, the use of continuous glucose monitoring, absent from this trial, would have gathered more comprehensive data on glycemic variability, postprandial excursions, and time in glycemic objectives. The lack of standardization between test centers in insulin titration methodology could also be considered a limitation. Furthermore, the capped insulin dose is rarely used in clinical trials in subjects with type 1 diabetes, making comparisons with other trials a challenge.
In summary, the ADJUNCT TWO trial demonstrated benefits of liraglutide as an adjunct to insulin treatment in subjects with type 1 diabetes with a capped insulin dose with respect to glycemic control, insulin dose, weight, and quality of life. The higher number of hypoglycemia and of hyperglycemia with ketosis in some of the liraglutide groups emphasizes the need for proper insulin titration and may ultimately limit the clinical utility of GLP-1RAs in a less well-supervised population with type 1 diabetes.
